Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06620913
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
None
First Post:
2024-09-27
Brief Title:
Clinico-immunological Characterization and Immune Tolerance Breakdown in CV2-autoimmunity
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Clinico-immunological Characterization and Immune Tolerance Breakdown in CV2-autoimmunity
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CarTo-CV2
Brief Summary:
Paraneoplastic neurological syndromes are rare syndromes caused by the remote effects of cancer They have an immune-mediated pathogenesis yet the underlying mechanisms are not fully elucidated CV2Collapsin response-mediator protein 5 CRMP5-IgG paraneoplastic neurological syndrome is characterized by heterogeneous clinical presentations affecting both central and peripheral nervous system and the most frequently associate tumor is small cell lung carcinoma Central nervous system involvement along with CSF and neuroimaging findings have not been fully described in the literature in CV2CRMP5 patients Unraveling the complexities of CV2CRMP5 paraneoplastic neurological syndrome is critical to improve diagnosis treatment and patients care Our intention is to perform a comprehensive analysis of the clinical characteristics and instrumental investigations of a large cohort of CV2CRMP5 patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None